Skip to main content

Precision Oncology 2.0™

Broadening the reach and impact of precision medicine

Welcome to the era of Precision Oncology 2.0™

Surgery Chemotherapy Radiation
Precision Oncology 1.0
Immuno-Oncology 1.0
Cell & Gene Therapy 1.0
Precision Oncology 2.0™

Aiming to deliver a fast, precise and lethal strike at cancer’s unique drivers

Before we launch a program against a new, high-value target, we always ask ourselves:


  • Can selective target inhibition improve patients’ survival or quality of life beyond what’s possible with the current standard treatment?
  • Can the target be dosed to achieve therapeutic effects without causing unmanageable and potentially toxic side effects?
  • Can inhibiting the target offer benefits as part of combination therapy?
Our Pipeline

Why our work matters

We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.


Meet our
leadership team

Our world-class team is comprised of experts in cancer biology, medicinal chemistry, next-generation chemical proteomics, computational chemistry and molecular biophysics, machine learning, and drug development. Together, they have architected a new and innovative approach to target and drug discovery.

Growing a thriving culture

The work environment we have created is as important to us as our science. We are looking for team members who share our cultural commitments.